Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

In a new study published in the journal GeroScience, VAS101 (Vasceptor®), a novel curcumin transdermal formulation developed ...

Correspondence to Professor Masaaki Murakami, Division of Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; ...

Introduction: The pro-inflammatory cytokine interleukin-23 (IL-23) has been implicated in colorectal cancer (CRC). Yet, the cell-specific contributions of IL-23 receptor (IL-23R) signaling in CRC ...

Sonnet BioTherapeutics Holdings, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent related to its modified form of Interleukin-18 ...

The best-selling author and podcaster on how to preserve robust physical, cognitive and emotional health, and how Medicine ...

Coronary artery disease has long been understood through the paradigm of epicardial coronary artery obstruction, causing ...

The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...

In Europe, these therapies were introduced between 2006 and 2013. The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors, with J&J’s Stelara (ustekinumab) leading the way ...

Shares of PDS Biotechnology Corporation (PDSB) drew investor attention on Thursday after the company reported ...